Acer Therapeutics (NASDAQ: ACER) is one of 297 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Acer Therapeutics to similar businesses based on the strength of its analyst recommendations, risk, dividends, institutional ownership, profitability, valuation and earnings.
Institutional & Insider Ownership
33.6% of Acer Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 6.9% of Acer Therapeutics shares are held by company insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Acer Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Acer Therapeutics Competitors||-5,117.95%||-418.31%||-40.70%|
This is a breakdown of recent ratings and price targets for Acer Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Acer Therapeutics Competitors||792||3133||11394||228||2.71|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.90%. Given Acer Therapeutics’ rivals higher possible upside, analysts clearly believe Acer Therapeutics has less favorable growth aspects than its rivals.
Volatility and Risk
Acer Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Acer Therapeutics’ rivals have a beta of 6.09, indicating that their average share price is 509% more volatile than the S&P 500.
Earnings & Valuation
This table compares Acer Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Acer Therapeutics||$2.90 million||-$7.97 million||-2.37|
|Acer Therapeutics Competitors||$290.00 million||$35.57 million||148.34|
Acer Therapeutics’ rivals have higher revenue and earnings than Acer Therapeutics. Acer Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Acer Therapeutics rivals beat Acer Therapeutics on 7 of the 9 factors compared.
Acer Therapeutics Company Profile
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Receive News & Ratings for Acer Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.